Prot # GS-US-196-0140: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a(PEG, Pegasys) and Ribavirin (RBV, Copegus) with

Project: Research project

Project Details

Effective start/end date3/9/113/9/14


  • PRA Health Sciences (GS-US-196-0140 // GS-US-196-0140)
  • Gilead Sciences, Inc (GS-US-196-0140 // GS-US-196-0140)